Apoptosis and cancer: insights molecular mechanisms and treatments

Paper Details

Review Paper 01/06/2012
Views (317) Download (9)

Apoptosis and cancer: insights molecular mechanisms and treatments

Md. Ataur Rahman, Md. Tipu Sultan, Md. Rokibul Islam
Int. J. Biomol. & Biomed.2( 1), 1-16, June 2012.
Certificate: IJBB 2012 [Generate Certificate]


Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment, but it is also involved in a wide range of pathological processes, including cancer. An understanding of the underlying mechanism of apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer by acting in the extrinsic/intrinsic pathway. Defects can occur at any point along these pathways, leading to malignant transformation of the affected cells, tumour metastasis and resistance to anticancer drugs. In particular, this review provides references concerning the apoptotic molecules, their interactions, the mechanisms involved in apoptosis resistance, and also the modulation of apoptosis for the treatment of cancer. Despite being the cause of problem, apoptosis plays an important role in the treatment of cancer as it is a popular target of many treatment strategies.


Abou-Nassar K, Brown JR. 2010. Novel agents for the treatment of chronic lymphocytic leukaemia. Clin Adv Haematol Oncol 8(12), 886-895.

Ahnen DJ.1997. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57, 267-271.

Ahnen DJ, Thompson H, Pamukcu R, Piazza GA. 1998. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis 19, 1353-1356.

Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A. 2011. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and upregulating BH3-only protein NOXA. J Biol Chem 286(28), 24882-24895.

Ambrosini G, Adida C, Altieri DC. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3, 917–921.

Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D. 2006. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut 55, 367-373.

Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P. 2011. p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 11, 203.

Bai L, Zhu WG. 2006. p53: structure, function and therapeutic applications. J Cancer Mol 2(4),141-153.

Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. 2011. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol 38(6), 1683-1694.

Bauer JH, Hefand SL. 2006. New tricks of an old molecule: lifespan regulation by p53. Aging Cell 5, 437-440.

Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. 2008. Targeted rescue of a destabilised mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105(30), 10360-10365.

Cao C, Mu Y, Hallahan DE, Lu B. 2004. XIAP and Survivin as therapeutic targets for radiation sensitisation in preclinical models of lung cancer. Oncogene 23, 7047-7052.

Cam L, Boucquey A, Coulomb-L’hermine A, Weber A, Horellou P. 2005. Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line. J Gene Med 7(1), 30-38.

Chène P. 2001. p53 as a drug target in cancer therapy. Expert Opin Ther Patents 11(6), 923-935.

Dai Y, Lawrence TS, Xu L. 2009. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Tranl Res 1(1), 1-15.

Danial NN. 2004. Korsmeyer SJ: Cell death: critical control points. Cell 116(2), 205-219.

Dewson G, Kluc RM. 2010. Bcl-2 family-regulated apoptosis in health and disease. Cell Health and Cytoskeleton 2, 9-22.

Du ZX, Zhang HY, Gao DX, Wang HQ, Li YJ, Liu GL. 2006. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Exp Mol Med 38, 230-240.

Fink SL, Cookson BT. 2005. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 73(4), 1907-1916.

Fulda S, Meyer E, Debatin KM. 2000. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21, 2283-2294.

Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. 2006. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs 24, 79-83.

Gasco M, Shami S, Crook T. 2002. The p53 pathway in breast cancer. Breast Cancer Res 4, 70-76.

Ghobrial IM, Witzig TE, Adjei AA. 2005. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55,178-194.

Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R, Olsson CA. 1999. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53, 440-445.

Goolsby C, Paniagua M, Tallman M, Gartenhaus RB. 2005. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukaemia. Cytometry B Clin Cytom 63(1), 36-46.

Gross A, McDonnell JM, Korsmeyer SJ. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13, 1899-1911.

Grossman D, McNiff JM, Li F, Altieri DC.1999. Expression and targeting of the apoptosis inhibitor, Survivin, in human melanoma. J Invest Dermatol 113(6),1076-1081.

Hacker G. 2000. The morphology of apoptosis. Cell Tissue Res 301, 5-17.

Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100, 57-70.

Hengartner MO. 2000. Apoptosis: corralling the corpses. Cell 104, 325-328.

Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC. 2003. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro andin vivo. Clin Cancer Res 9, 2826-2836.

Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, Oliff IA, Rummel MJ, Österborg A. 2008. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukaemia. Invest New Drugs 26(2), 139-149.

Jones SF, Kuhn JG, Greco, FA, Raefsky EL, Hainsworth JD, Dickson NR, Thompson DS. Willcutt NT, White MB, Burris HA. 2005. A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. Clin Lung Cancer 6, 361-366.

John Nemunaitis, Ian Ganly, Fadlo Khuri, James Arseneau, Joseph Kuhn, Todd McCarty, Stephen Landers, Phillip Maples, Larry Rome, Britta Randlev, Tony Reid, Sam Kaye, David Kirn. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 60, 6359.

Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S, Imamura M. 2005. Downregulation of Survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138(2), 299-305.

Kang MH, Reynolds CP. 2009. Bcl-2  inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15, 1126-1132.

Karp G. 2008. Cell and molecular biology: Concepts and experiments. 5th edition. John New Jersey: Wiley and Sons, 653-657.

Kerr JFR, Wyllie AH, Currie AR. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 239-257.

Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schützner J, Zatloukal P, Benkova K. 2009. Increased expression of inhibitor of apoptosis proteins, Survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 35(6),1449-1462.

Kroemer G, Galluzzi L, Brenner C. 2007. Mitochondrial membrane permeabilisation in cell death. Physiol Rev 87(1), 99-163.

Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G. 2005. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 12, 1463-1467.

Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wölfel T, Theobald M. 2002. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 9(13), 833-843.

Kumar  V, Abbas  AK,  Fausto N,  Aster JC. 2010. Robins and Cotran: pathologic basis of disease. 8th edition. Philadelphia: Saunders Elsevier, 25-32.

LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. 2008. IAP-targeted therapies for cancer. Oncogene 27(48), 6252-6275.

Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ. 2008. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13(5), 454-463.

Lavrik IN, Golks A, Krammer PH. 2005. Caspases: pharmacological manipulation of cell death. J Clin Invest 115, 2665-2672.

Lavrik I, Golks A, Krammer PH. 2005. Death receptor signaling. J Cell Sci 118, 265-267.

Levine AJ, Momand J, Finlay CA. 1991. The p53 tumour suppressor gene. Nature 351(6326), 453-456.

Liu Q, Dong C, Li L, Sun J, Li C, Li L. 2011. Inhibitory effects of the survivin siRNA transfection on human lung adenocarcinoma cells SPCA1 and SH77. Zhongguo Fei Ai Za Zhi 14(1), 18-22.

Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S. 2011. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 10(5), 902-914.

Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A, Nicholson DW. 2000. From bench to clinic with apoptosisbased therapeutic agents. Nature 407, 810–816.

McCarthy NJ, Evan GI. 1998. Methods for detecting and quantifying apoptosis. Curr Top Dev Biol 36, 259-278.

Merkle CJ. 2009. Cellular adaptation, injury, and death. In Pathophysiology: concepts of altered health states. 8th edition. Edited by Porth CM, Matfin G. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins, 94-111.

Minn AJ, Vélez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB. 1997. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 385(6614), 353-357.

Minn AJ, Rudin CM, Boise LH, Thompson CB. 1995. Expression of Bcl-XL can confer a multidrug resistance phenotype. Blood 86,1903-1910.

Miquel C, Borrini F, Grandjouan S, Aupérin A, Viguier J, Velasco V, Duvillard P, Praz F, Sabourin JC. 2005. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am J Clin Pathol 23(4), 562-570.

Mohan H. 2010. Textbook of pathology. 5th edition. New Delhi: Jaypee Brothers Medical Publishers, 21-60.

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Jeffry Evans TR, Sansom OJ. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. PNAS 107(1), 246-251.

O’Brien MA, Kirby R. 2008. Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care 18(6), 572-585.

Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D. 2005. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 54(9), 1298-1308.

Ohnishi K, Scuric Z, Schiesti RH, Okamoto N, Takahashi A, Ohnishi T. 2006. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat Res 166, 454-462.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042), 677-681.

Oren M, Rotter V. 1999. Introduction: p53–the first twenty years. Cell Mol Life Sci 55, 9-11.

Philchenkov A, Zavelevich M, Kroczak TJ, Los M. 2004. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 26(2), 82-97.

Pennati M, Folini M, Zaffaroni N. 2007. Targeting Survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28(6), 1133-1139.

Pepper C, Hoy T, Bentley DP. 1997. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 76(7), 935-938.

Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. 1995. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55, 4438.

Rai KR, Moore J, Wu J, Novick SC, O’Brien SM. 2008. Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for replased/refractory chronic lymphocytic leukaemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study [abstract]. J Clin Oncol 26, 7008.

Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht A. 2002. Characterisation of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21(14), 2119-2129.

Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP.1990. p53 mutations in colorectal cancers. Proc Natl Acad Sci USA 87, 7555-7559.

Reed JC.1997. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in haematologic malignancies. Semin Haematol 34, 9-19.

Rohn JL, Noteborn MH. 2004. The viral death effector Apoptin reveals tumour-specific processes. Apoptosis 9, 315-322.

Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumuors of patients with lung cancer. Nature Medicine 2(9), 985-991.

Saraste A, Pulkki K. 2000. Morphologic and biochemical hallmarks of apoptosis. Cardiovascular Res 45, 528-537.

Schneider P, Tschopp J. 2000. Apoptosis induced by death receptors. Pharm Acta Helv 74, 281-286.

Shangary S, Wang S. 2008. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49, 223-241.

Sharma H, Sen S, Lo ML Mraiggiò, Singh N. 2005. Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitises head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 4,720-727.

Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang. 2008. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumours and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105(10), 3933-3938.

Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. 2010. Overexpression of surviving initiates haematologic malignancies in vivo. Leukaemia 24(11), 1920-1926.

Soriano AF, Helfrich B, Chan DC, Heasley L E, Bunn P AJR, Chou TC. 1999. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer  cell lines. Cancer Res 59, 6178-6184.

Sun H, Liu L, Lu J, Qiu S, Yang CY, Yi H, Wang S. 2010. Cyclopeptide Smac mimetics as antagonists of IAP proteins. Bioorg Med Chem Lett 20(10), 3043-3046.

Suzuki K, Matusubara H. 2011. Recent advances in p53 research and cancer treatment. J. Biomed Biotech 2011, 978312.

Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH. 2004. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 53(7), 633-641.

Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM.1984. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation. Science 226, 1097-1099.

Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW. 2011. Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J. Biomed Biotechnol 2011, 702146.

Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K. 2007. Cancer-derived p53 mutants suppress p53-target gene expression–potential mechanism for gain of function of mutant p53. Nucl Acids Res 35(6), 2093-2104.

Vucic D, Fairbrother WJ. 2007. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13(20), 5995-6000.

Wei Y, Fan T, Yu M. 2008. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin 40(4), 278-288.

Wu X, Liu X, Sengupta J, Bu Y, Yi F, Wang C, Shi Y, Zhu Y, Jiao Q, Song F. 2011. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Indian J Exp Biol 49(2), 105-112.

Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Saitou Y, Sugimoto K, Nakano T. 2005. Targeting of X-linked inhibitor of apoptosis protein or Survivin by short interfering RNAs sensitises hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep 12, 1211-1316.

Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M, Saito I, Kanegae Y, Matsuda H. 1999. Cancer gene therapy using a pro- apoptotic gene, caspase-3. Gene Ther 6(12),1952-1959.

Yang CT, Li JM, Weng HH, Li YC, Chen HC, Chen MF. 2010. Adenovirus-mediated transfer of siRNA against Survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Cancer Gene Ther 17, 120-130.

Zaffaroni N, Pennati M, Daidone MG. 2005. Survivin as a target for new anticancer interventions J Cell Mol Med 9, 360–372.

Zhang X, Li N, Wang YH, Huang Y, Xu NZ, Wu LY. 2009. Effects of Survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP. Zhonghua Zhong Liu Za Zhi 31(3), 174-177.

Ziegler U, Groscurth P. 2004. Morphological features of cell death. News Physiol Sci 19, 124-128.